Phase 3 Completed N=466 Randomized Double-blind Treatment

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Glaucoma · Hypertension

Source: ClinicalTrials.gov NCT01830140 ↗

Enrolled (actual)

466

Serious AEs

0.9%

Results posted

May 2015

Primary outcomePrimary: Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye — 34.3; 39.1 Percentage of Patients

Summary

This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye	34.3; 39.1	—

Eligibility Criteria

Inclusion Criteria

Diagnosis of glaucoma or ocular hypertension

Exclusion Criteria

Active ocular disease other than glaucoma or ocular hypertension
Require chronic use of ocular medications other than the study medication during the study (intermittent use of artificial tear solution will be permitted)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01830140). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.